FranΓ§aisπ See the interactive version (live chart) β
| Metric | Value | What it means |
|---|---|---|
| P/E (price / earnings) | 35.9 | The higher, the more growth the market expects. |
| Forward P/E | 31.7 | On next year's expected earnings. Lower than current P/E = rising earnings. |
| PEG (P/E Γ· growth) | 0.97 | Below 1 = cheap given growth; above 2 = expensive. |
| Net margin | 18% | Share of revenue that ends up as profit. |
| Revenue growth | 17% | Pace of revenue growth. |
| Price-to-book | 39.3 | Price relative to book value. |
| Market cap | $17.1 B | Total market value of the company. |
| Dividend yield | β | No dividend currently. |
| Year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2022 | $1.5 B | $245 M | 17% |
| 2023 | $1.9 B | $283 M | 15% |
| 2024 | $2.1 B | $404 M | 19% |
| 2025 | $2.5 B | $451 M | 18% |
π Open the interactive Medpace page (charts, live news) β
Medpace has a P/E of 35.9 (forward P/E 31.7) and a PEG of 0.97. A PEG below 1 is rather cheap given growth, above 2 is expensive. Verdict: rather cheap given growth.
Medpace's net margin is about 18% β the share of revenue that ends up as net profit.
Latest known revenue: $2.5 B for net income of $451 M. The year-by-year breakdown is in the income statement above.
Medpace (MEDP) has a market cap of about $17.1 B.
No, Medpace does not currently pay a dividend (it reinvests earnings).
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
Explore JPI Invest for free β How it works: the method β
β οΈ Educational information, not investment advice. Data: Yahoo Finance, recomputed by JPI Invest. A stock can be Β« cheap Β» for a bad reason.